Impact of intra-tumoral heterogeneity detected by next-generation sequencing on acute myeloid leukemia survival

Leuk Lymphoma. 2020 Dec;61(13):3269-3271. doi: 10.1080/10428194.2020.1797016. Epub 2020 Jul 26.

Authors

Wade L Schulz^{1

2}, Henry M Rinder¹, Thomas J S Durant^{1

2}, Christopher A Tormey¹, Richard Torres¹, Brian R Smith¹, Karl M Hager¹, John Greg Howe¹, Alexa J Siddon^{1

3}

Affiliations

¹ Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA.
² Center for Outcomes Research & Evaluation, Yale New Haven Hospital, New Haven, CT, USA.
³ Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.

PMID: 32715805
DOI: 10.1080/10428194.2020.1797016

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

High-Throughput Nucleotide Sequencing*
Humans
Leukemia, Myeloid, Acute* / diagnosis
Leukemia, Myeloid, Acute* / genetics
Mutation